Q2 2025 Nanoform Finland Oyj Earnings Call Transcript
Key Points
- Nanoform Finland PLC (FRA:4YL) has seen significant growth in the number of signed projects and revenue, with a 23% increase in the first half compared to last year.
- The company has successfully reduced costs, improving cash flow and maintaining a cash runway of over two years with EUR 33 million in cash at the end of the quarter.
- Nanoform has signed its first license and supply agreement in Germany, marking a significant milestone in its commercial progress.
- The company has expanded its customer base geographically, including new projects from Japan, enhancing its market diversity.
- Nanoform's technology has shown promising results in clinical studies, with nanoenzalutamide demonstrating matching plasma concentration to reference products, indicating potential for market progression.
- Despite growth, the company acknowledges that the pace could be faster, especially in a challenging CDMO market.
- There is a potential need for a non-inferiority efficacy trial for nanoenzalutamide due to lower peak plasma concentrations, which could impact regulatory approval processes.
- The gross margin of 98% is higher than sustainable long-term expectations, with a target of maintaining above 90%.
- The company faces challenges in the tough CDMO environment, which could impact future growth and project signings.
- Regulatory approval processes, such as the Fimea inspection, could delay market entry for new products if not passed promptly.
Welcome to the conference call. (Operator Instructions)
Now I will hand the conference over to the speakers. Please go ahead.
Good afternoon all, and a warm welcome to Nanoform's Second Quarter 2025 Report Presentation. My name is Henri von Haartman, and I'm your Director of Investor Relations. Today, our CEO, Edward Haeggstrom; CFO, Albert Haeggstrom; Chief Commercial Officer, Christian Jones; and Chief Development Officer, Peter Hanninen, will present to you.
This presentation is webcasted through Investor Caller, and there is also the possibility to call in and listen by phone. The presentation slides that are shown throughout the webcast can also be found on our web page in the Investors section.
After the presentation, we will hold a Q&A and it's possible to ask questions by calling in. We will today start with an introduction and then key business highlights, then financials, then commercial performance, and we will conclude with our product kernels.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
